{
  "abstract": "Since the introduction of non-dilated left ventricular cardiomyopathy (NDLVC) as a distinct clinical entity by the European Society of Cardiology (ESC) in 2023, this phenotype has been a subject of significant interest and ongoing investigation.1 Nearly 2 years on, a substantial body of evidence has been accumulated on NDLVC, contributing to a more refined understanding of the condition. However, a word of caution is warranted: current literature remains entirely retrospective. What are the implications of this? First, the available data originate predominantly from large cardiomyopathy centres, which maintain extensive long-term registries often encompassing hundreds, even thousands, of patients. Second, patients with NDLVC have typically been identified through retrospective ‘extraction’ from these databases using the newly proposed ESC diagnostic criteria. While such an approach is methodologically valid and logistically convenient, it carries inherent limitations: preselection bias (younger patients, positive family history of cardiomyopathy, severe courses and advanced structural and functional abnormalities), enrolment spanning decades and finally the process of ‘extraction’ typically relies on inputting a limited set of prespecified criteria into database search engines, a method that inevitably reduces the diagnostic process to an overly simplified step, and thus fails to capture the nuanced, thorough and often intricate clinical evaluations.",
  "authors": [
    {
      "affiliations": [
        "Department of Cardiac and Vascular Diseases, Jagiellonian University Medical College, Saint John Paul II Hospital, Krakow, Krakow, Poland"
      ],
      "name": "Pawel Rubis"
    }
  ],
  "title": "Phenotyping non-dilated left ventricular cardiomyopathy: just the beginning of the journey",
  "uid": "3b07d7e3-f29e-55b9-8a0a-15b7ba5c775e"
}